What is HC Wainwright’s Estimate for LXRX FY2027 Earnings?

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) – Investment analysts at HC Wainwright issued their FY2027 earnings per share estimates for Lexicon Pharmaceuticals in a research note issued on Thursday, March 5th. HC Wainwright analyst J. Pantginis anticipates that the biopharmaceutical company will earn ($0.21) per share for the year. HC Wainwright has a “Buy” rating and a $6.00 price target on the stock. The consensus estimate for Lexicon Pharmaceuticals’ current full-year earnings is ($0.66) per share. HC Wainwright also issued estimates for Lexicon Pharmaceuticals’ FY2028 earnings at ($0.18) EPS.

Several other equities research analysts have also recently issued reports on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Lexicon Pharmaceuticals in a research report on Thursday, January 22nd. Wall Street Zen downgraded shares of Lexicon Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, November 15th. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Lexicon Pharmaceuticals currently has a consensus rating of “Hold” and a consensus price target of $3.95.

Lexicon Pharmaceuticals Trading Up 4.3%

NASDAQ LXRX opened at $1.71 on Friday. The company has a market cap of $621.53 million, a P/E ratio of -12.21 and a beta of 0.94. Lexicon Pharmaceuticals has a 12 month low of $0.32 and a 12 month high of $1.83. The company has a debt-to-equity ratio of 0.47, a current ratio of 5.64 and a quick ratio of 5.63. The company has a 50-day moving average of $1.36 and a 200-day moving average of $1.33.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last issued its quarterly earnings results on Thursday, March 5th. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.03. The firm had revenue of $5.49 million for the quarter, compared to analyst estimates of $3.14 million. Lexicon Pharmaceuticals had a negative return on equity of 40.53% and a negative net margin of 101.08%.

Insider Activity

In related news, Director Invus Global Management, Llc bought 1,538,462 shares of the company’s stock in a transaction that occurred on Monday, February 2nd. The shares were acquired at an average cost of $1.30 per share, for a total transaction of $2,000,000.60. Following the acquisition, the director owned 1,538,462 shares in the company, valued at $2,000,000.60. This represents a ∞ increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Raymond Debbane purchased 100,000 shares of Lexicon Pharmaceuticals stock in a transaction that occurred on Monday, February 23rd. The shares were bought at an average cost of $1.47 per share, for a total transaction of $147,000.00. Following the completion of the transaction, the director directly owned 1,904,186 shares in the company, valued at $2,799,153.42. This represents a 5.54% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders bought 1,790,462 shares of company stock valued at $2,369,981 in the last ninety days. Company insiders own 13.90% of the company’s stock.

Institutional Trading of Lexicon Pharmaceuticals

Large investors have recently bought and sold shares of the company. Virtu Financial LLC acquired a new stake in Lexicon Pharmaceuticals during the 4th quarter valued at approximately $42,000. Invesco Ltd. raised its position in shares of Lexicon Pharmaceuticals by 14.1% in the 4th quarter. Invesco Ltd. now owns 594,883 shares of the biopharmaceutical company’s stock valued at $684,000 after purchasing an additional 73,480 shares in the last quarter. Millennium Management LLC boosted its stake in shares of Lexicon Pharmaceuticals by 25.9% during the 4th quarter. Millennium Management LLC now owns 4,821,733 shares of the biopharmaceutical company’s stock valued at $5,545,000 after buying an additional 991,073 shares during the last quarter. Ishara Investments LP purchased a new position in shares of Lexicon Pharmaceuticals during the 4th quarter valued at approximately $1,012,000. Finally, ExodusPoint Capital Management LP purchased a new position in shares of Lexicon Pharmaceuticals during the 4th quarter valued at approximately $309,000. Institutional investors and hedge funds own 74.70% of the company’s stock.

More Lexicon Pharmaceuticals News

Here are the key news stories impacting Lexicon Pharmaceuticals this week:

• Positive Sentiment: Q4 results beat expectations — GAAP EPS of -$0.04 vs. -$0.07 consensus and revenue of $5.49M vs. $3.14M expected, which relieved near-term execution concerns and likely helped the stock. Earnings beat summary
• Positive Sentiment: Clinical progress: management confirmed sotagliflozin pivotal milestones are on schedule (including planned NDA resubmission in T1D and enrollment of the SONATA HCM study) and reported a positive End‑of‑Phase‑2 meeting with the FDA for pilavapadin, supporting Phase 3 readiness. These program updates materially de‑risk future value drivers. Press release with clinical updates
• Positive Sentiment: Balance-sheet boost — management disclosed more than $100M in additional cash from a capital raise plus a Novo Nordisk milestone payment, improving runway and reducing near‑term financing risk. Press release with financing detail
• Positive Sentiment: Analyst upgrade / price-target raise — H.C. Wainwright reiterated a Buy rating and raised its target to $6, signaling bullish analyst conviction and providing a large implied upside that can attract momentum buyers. Analyst note / PT raise
• Neutral Sentiment: Management hosted an earnings call and published slides/transcript; these provide more detail for investors but are informational rather than catalytic. Earnings call transcript
• Negative Sentiment: Company remains unprofitable with a negative net margin (~96.8%) and negative return on equity; consensus still forecast a full‑year loss (current consensus ~ -$0.66 EPS), so fundamentals remain challenged absent clinical or commercial validation. Earnings / metrics summary
• Negative Sentiment: Biotech execution and regulatory risk persist — upcoming clinical readouts and the NDA resubmission are binary events that could reverse gains if outcomes disappoint. Clinical & regulatory update

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc is a biopharmaceutical company focused on the discovery and development of novel medicines through its proprietary genome biology platform. By leveraging large-scale gene knockout libraries, the company identifies potential therapeutic targets and advances them through preclinical and clinical development. Lexicon’s approach emphasizes the translation of genetic insights into targeted therapies for a range of human diseases.

The company’s most advanced product is telotristat ethyl (sold under the brand name XERMELO), an oral treatment approved for the management of carcinoid syndrome diarrhea in patients inadequately controlled by somatostatin analog therapy.